Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer
Version of Record online: 9 OCT 2012
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL
Volume 110, Issue 11c, pages E1228–E1236, December 2012
How to Cite
Laurberg, J. R., Brems-Eskildsen, A. S., Nordentoft, I., Fristrup, N., Schepeler, T., Ulhøi, B. P., Agerbæk, M., Hartmann, A., Bertz, S., Wittlinger, M., Fietkau, R., Rödel, C., Borre, M., Jensen, J. B., Ørntoft, T. and Dyrskjøt, L. (2012), Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU International, 110: E1228–E1236. doi: 10.1111/j.1464-410X.2012.11564.x
- Issue online: 21 DEC 2012
- Version of Record online: 9 OCT 2012
- Accepted for publication 11 July 2012
FIG. S1. Validation of antibody specificity. A, Western blot of cancer tissue using antibodies against MRE11. Lane 1, 2 contains nuclear extracts from two different bladder tumours. B, Western blot of Cos-7 green monkey Tip60α-eGFP transfected cell-line using antibodies against TIP60.
FIG. S2. Kaplan–Meier survival curves of DSS. DSS for cohort A, B and C (A). DSS as function of combined TIP60 and P16 in cohort A (B) and cohort B (C). DSS as function of combined MRE11 and P16 in cohort B (D) and cohort C (E).
Table S1 Marker expression according to clinical parameters.
|bju11564_sm_FigS1.pdf||354K||Supporting info item|
|bju11564_sm_FigS2.pdf||394K||Supporting info item|
|bju11564_sm_TabS1.doc||108K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.